ArticleACS omega2026
Amphiphilic Lipid-Polymer Triblock Architectures as Nanocarriers for Therapeutic Delivery.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
This study investigates the formation and characterization of nanocarriers derived from the self-assembly of amphiphilic lipid-polymer hybrids (LPHs) engineered with a symmetric ABA block copolymer architecture. In this design, the terminal A-blocks comprise branched hydrophobic fatty acid (FA) moieties, while the central B-block consists of a hydrophilic polymer segment, either polyethylene glycol (PEG) or a polypeptide-based glycine-lysine (GK) construct. By systematically varying the degree of branching within the hydrophobic blocks and the chemical identity of the hydrophilic segments, this work elucidates how architectural and compositional features govern the physicochemical behavior of the resulting nanoparticles (NPs). Comprehensive characterization, including 1D and 2D NMR spectroscopy, differential scanning calorimetry (DSC), dynamic light scattering (DLS), transmission electron microscopy (TEM), and in vitro cellular assays, revealed that both the morphology and mechanical properties of the NPs could be finely tuned through precise molecular design. Results indicate that NPs within the therapeutic size window (<200 nm) and with near-neutral surface charges meet key criteria for systemic delivery. Encapsulation efficiencies (EE%) for small-molecule therapeutics (doxorubicin and curcumin) ranged from 11-33%. Notably, modulation of hydrophilic block identity produced distinct NP surface chemistries that appear to influence cellular uptake behavior, while variations in hydrophobic block branching affected particle size distributions and nanostructural integrity. Substitution of inert PEG with the cationic, biofunctional GK polypeptide was associated with increased cellular uptake and enhanced doxorubicin delivery efficacy in breast cancer cell models. Additionally, increasing hydrophobic branching density (4FA versus 2FA) was correlated with improved colloidal stability and the formation of larger internal hydrophobic domains, supporting higher drug loading capacity. Collectively, these results provide an initial in vitro proof of concept and begin to establish structure-property-function relationships that expand the design space of amphiphilic LPH nanocarriers. While promising as an exploratory study, the work lays the groundwork for future studies needed to evaluate biological performance, safety, and translational potential.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.